Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V1FF
|
|||
| Former ID |
DIB012482
|
|||
| Drug Name |
Davunetide
|
|||
| Synonyms |
Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
Click to Show/Hide
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Phase 3 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9] | Discontinued in Phase 2 | [2] | ||
| Company |
Allon Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | Modulator | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Alzheimer's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reelin signaling pathway | ||||
| Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | Notch Signaling Pathway | |||
| IL-2 Signaling Pathway | ||||
| MAPK Signaling Pathway | ||||
| Copper homeostasis | ||||
| Kit receptor signaling pathway | ||||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| Apoptotic execution phase | ||||
| IL-5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014948) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.